Legal DealFolio - UBS/Citigroup - Luye Pharma Group Initial Public Offering

Herbert Smith Freehills has advised UBS AG, Hong Kong Branch; Citigroup Global Markets Asia Limited; and CITIC Securities Corporate Finance (HK) Limited in relation to their role as the underwriters and joint sponsors of the Initial Public Offering (IPO) of Luye Pharma Group Ltd. (Luye) and its listing on the Hong Kong Stock Exchange. The IPO raised USD764 million, making it the world's largest pharmaceutical company IPO in three years. Luye focuses on developing, producing and distributing innovative pharmaceutical products in three of China's largest and fastest growing therapeutic areas: oncology, cardiovascular system and alimentary tract and metabolism. Luye listed on the Hong Kong Stock Exchange on 9 July 2014. The move represents its second run as a public company. Previously, Luye traded on the Singapore Exchange, but was taken private in 2012 by Chinese private equity funds CDH Capital, Citic Private Equity and New Horizon Capital, and Luye's founders. The Herbert Smith Freehills team was led by Hong Kong partners Gary Lock and Kevin Roy who were supported by associates Ruth Lau, Jackie Chen, Eugene Lau and George Wu.

Deal Date:	16-07-2014	Practice Area:	Equity Capital Markets
Deal Title:	UBS/Citigroup - Luye Pharma Group Initial Public Offering	Industry:	Pharmaceuticals & Biotechnology
Description:	Herbert Smith Freehills has advised UBS AG, Hong Kong Branch; Citigroup Global Markets Asia Limited; and CITIC Securities Corporate Finance (HK) Limited in relation to their role as the underwriters and joint sponsors of the Initial Public Offering (IPO) of Luye Pharma Group Ltd. (Luye) and its listing on the Hong Kong Stock Exchange. The IPO raised USD764 million, making it the world's largest pharmaceutical company IPO in three years. Luye focuses on developing, producing and distributing innovative pharmaceutical products in three of China's largest and fastest growing therapeutic areas: oncology, cardiovascular system and alimentary tract and metabolism. Luye listed on the Hong Kong Stock Exchange on 9 July 2014. The move represents its second run as a public company. Previously, Luye traded on the Singapore Exchange, but was taken private in 2012 by Chinese private equity funds CDH Capital, Citic Private Equity and New Horizon Capital, and Luye's founders. The Herbert Smith Freehills team was led by Hong Kong partners Gary Lock and Kevin Roy who were supported by associates Ruth Lau, Jackie Chen, Eugene Lau and George Wu.
Financial Center:	Hong Kong	Value:	500.01-1000.00
Advised Party:	Lead Managers	Law Firm	Herbert Smith Freehills
Issuer Jurisdiction-	China	Listing Jurisdiction-	Hong Kong
Classification:	Initial Public Offerings Hong Kong Stock Exchange	Lawyer	Gary Lock

Practice Areas -

Equity Capital Markets Law Firms and Lawyers

Practice Areas - Equity Capital Markets Law Firms and Lawyers